Find and Pitch Jounalists, Get Your Story Covered

Tags: apps instagram Meta service outage multiple sclerosis

	Profile	Recent Articles on Subject
1	1387865 PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	NICE nod for Darzalex with lenalidomide and dexamethasone - about 1 year ago
2	Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA Healthcareoncologypharmacyeducation	Personalizing Treatments and Patient Education - 6 days ago Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7 - 20 days ago Real-World Considerations for New Therapies - 27 days ago Impact of Transplant Eligibility on Treatment Selection - about 1 month ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Arcellx to present positive data on multiple myeloma treatments - 8 days ago Darzalex subcutaneous regimen approved by European Commission - 22 days ago Scotland first in UK to approve new myeloma treatment - 2 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 9 days ago
5	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma - 21 days ago Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options - 7 months ago Subcutaneous Daratumumab Plus VRd Significantly Improved PFS, Increased Depth of Response in Patients With Newly Diagnosed Multiple Myeloma - 11 months ago AI Model Can Differentiate Prefibrotic Primary Myelofibrosis From Essential Thrombocythemia With High Accuracy - 11 months ago Assessing Clinical Trial Efficacy vs Real-World Effectiveness in the Treatment of Multiple Myeloma - 11 months ago
6	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma - about 1 month ago Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers - 2 months ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - 9 months ago Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancer - 10 months ago Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS - 12 months ago
7	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma - 3 months ago Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs - 7 months ago
8	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 4 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Why Some Myeloma Patients Refuse Stem Cell Transplant - 11 months ago
9	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA Approves Earlier Use of CAR-T Products for Myeloma - 7 months ago Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials - 11 months ago
10	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy - 7 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 12 months ago

Journalists covering Multiple Myeloma